Current Breast Cancer Statistics

GITNUXREPORT 2026

Current Breast Cancer Statistics

With 2023 still setting the pace, the US projected 297,790 new invasive breast cancer cases and 43,700 deaths, even as survival for localized disease reaches 99% but drops to 30% for distant cancers. This Current Breast Cancer page pairs those survival gaps with the latest incidence and mortality trends, plus who is most affected and why stage at diagnosis matters.

150 statistics35 sources5 sections14 min readUpdated 1 mo ago

Key Statistics

Statistic 1

In the United States, an estimated 297,790 new cases of invasive breast cancer were diagnosed in 2023

Statistic 2

In the United States, an estimated 43,700 deaths from breast cancer were projected for 2023

Statistic 3

In the United States, the 5-year relative survival rate for breast cancer is 91% (diagnosed 2014–2020)

Statistic 4

In the United States, the 5-year relative survival rate for localized breast cancer is 99%

Statistic 5

In the United States, the 5-year relative survival rate for regional breast cancer is 86%

Statistic 6

In the United States, the 5-year relative survival rate for distant breast cancer is 30%

Statistic 7

In the United States, breast cancer is estimated to account for 30% of all new cancer cases in women

Statistic 8

In the United States, breast cancer is estimated to account for 28% of new cancer cases among women

Statistic 9

In the United States, an estimated 1 in 8 women will be diagnosed with breast cancer over the course of her lifetime

Statistic 10

In the United States, an estimated 1 in 42 women will die of breast cancer

Statistic 11

In the United States, breast cancer accounts for about 15% of all cancer deaths in women

Statistic 12

The age-adjusted incidence rate of female breast cancer in the United States (all races) was 128.9 per 100,000 in 2020

Statistic 13

The age-adjusted incidence rate of breast cancer in the United States (all races) was 131.8 per 100,000 in 2019

Statistic 14

The age-adjusted incidence rate of breast cancer in the United States (all races) was 127.5 per 100,000 in 2021

Statistic 15

The age-adjusted mortality rate of breast cancer in the United States (all races) was 23.1 per 100,000 in 2020

Statistic 16

The age-adjusted mortality rate of breast cancer in the United States (all races) was 22.9 per 100,000 in 2019

Statistic 17

The age-adjusted mortality rate of breast cancer in the United States (all races) was 22.4 per 100,000 in 2021

Statistic 18

In the United States, about 63% of breast cancers are diagnosed at the localized stage

Statistic 19

In the United States, about 30% of breast cancers are diagnosed at the regional stage

Statistic 20

In the United States, about 6% of breast cancers are diagnosed at the distant stage

Statistic 21

In the United States, about 1% of breast cancers are diagnosed at an unknown stage

Statistic 22

In the United States, in 2023, an estimated 55,720 new cases of in situ breast cancer (DCIS) were expected

Statistic 23

In the United States, in 2023, an estimated 4,640 deaths were expected from breast cancer

Statistic 24

Breast cancer incidence rates in the United States are higher in Black women than in White women

Statistic 25

In the United States, breast cancer death rates are higher for Black women than for White women

Statistic 26

In the United States, breast cancer survival is higher for White women than for Black women

Statistic 27

Globally, there were 2.3 million new cases of breast cancer in 2020

Statistic 28

Globally, there were 685,000 deaths from breast cancer in 2020

Statistic 29

In 2020, breast cancer had the highest number of new cancer cases among cancers

Statistic 30

In 2020, breast cancer was the second-leading cause of cancer death worldwide

Statistic 31

The most common type of breast cancer is invasive ductal carcinoma, accounting for 70% to 80% of cases

Statistic 32

Invasive lobular carcinoma accounts for 10% to 15% of invasive breast cancers

Statistic 33

Ductal carcinoma in situ (DCIS) accounts for about 20% of new breast cancer diagnoses in the United States

Statistic 34

Triple-negative breast cancer accounts for about 10% to 20% of all breast cancers

Statistic 35

HER2-positive breast cancer accounts for about 15% to 20% of breast cancers

Statistic 36

Hormone receptor–positive (ER-positive and/or PR-positive) breast cancer makes up about 70% of breast cancers

Statistic 37

Luminal A breast cancer is the most common molecular subtype, accounting for 30% to 60% of cases

Statistic 38

Luminal B breast cancer accounts for 10% to 20% of cases

Statistic 39

HER2-enriched breast cancer accounts for about 10% to 15% of cases

Statistic 40

Basal-like breast cancer overlaps with triple-negative breast cancer and is associated with higher relapse risk

Statistic 41

BRCA1 mutations account for about 45% to 65% of hereditary breast cancers

Statistic 42

BRCA2 mutations account for about 25% to 35% of hereditary breast cancers

Statistic 43

About 5% to 10% of breast cancers are hereditary, often linked to gene mutations like BRCA1 and BRCA2

Statistic 44

Women with a BRCA1 mutation have about a 65% lifetime risk of developing breast cancer

Statistic 45

Women with a BRCA2 mutation have about a 45% lifetime risk of developing breast cancer

Statistic 46

Lifetime risk of breast cancer for women with both BRCA1 and BRCA2 mutations is higher

Statistic 47

A first-degree relative with breast cancer increases risk

Statistic 48

Having a mother, sister, or daughter with breast cancer nearly doubles risk

Statistic 49

Risk increases with age; the majority of breast cancers occur after age 50

Statistic 50

The median age at diagnosis of breast cancer in the US is 62

Statistic 51

Men account for about 1% of all breast cancer cases

Statistic 52

Approximately 99% of breast cancer occurs in women

Statistic 53

Having a first period before age 12 is a risk factor associated with increased breast cancer risk

Statistic 54

Having menopause after age 55 is a risk factor for increased breast cancer risk

Statistic 55

Not having children or having first child after age 30 increases risk

Statistic 56

Breastfeeding for at least 6 months is associated with reduced breast cancer risk

Statistic 57

Alcohol consumption increases risk; even 1 drink per day is associated with increased risk

Statistic 58

Overweight and obesity after menopause increase breast cancer risk

Statistic 59

Physical activity reduces risk of breast cancer

Statistic 60

Women who took hormone therapy (combined estrogen and progestin) have increased breast cancer risk

Statistic 61

Screening mammography can detect breast cancer before symptoms

Statistic 62

The USPSTF recommends biennial screening mammography for women aged 40 to 74

Statistic 63

The USPSTF recommends screening mammography for women aged 40 to 74 with individual decision-making

Statistic 64

The USPSTF recommendation specifies biennial screening mammography (every 2 years) for average-risk women aged 40 to 74

Statistic 65

For women at high risk, screening with MRI and mammography may be recommended annually

Statistic 66

The American Cancer Society recommends that women at high risk get a breast MRI and a mammogram every year

Statistic 67

The American Cancer Society recommends that average-risk women start annual mammograms at age 45

Statistic 68

The American Cancer Society recommends annual mammograms at age 45 to 54

Statistic 69

The American Cancer Society recommends mammograms every year or every 2 years at age 55 and older

Statistic 70

Breast self-exam is not recommended as a screening test by USPSTF for all women

Statistic 71

Clinical breast exam is not recommended as a screening test by USPSTF for average-risk women

Statistic 72

For high-risk women, MRI screening is recommended in addition to mammography

Statistic 73

Diagnostic mammography is used to evaluate abnormal screening mammogram results

Statistic 74

Ultrasound can be used to evaluate lumps or abnormal mammogram findings

Statistic 75

Breast MRI is used to evaluate some abnormal mammogram results and for high-risk screening

Statistic 76

The sensitivity of mammography varies by age and breast density

Statistic 77

In the US, about 50% of women have dense breast tissue

Statistic 78

Dense breast tissue is associated with higher risk of breast cancer and reduced mammography sensitivity

Statistic 79

Breast biopsy is required to confirm diagnosis of breast cancer

Statistic 80

Core needle biopsy is often used to obtain tissue samples for diagnosis

Statistic 81

Fine needle aspiration may be used in some cases to sample fluid or tissue

Statistic 82

Sentinel lymph node biopsy is used to stage early breast cancer

Statistic 83

Axillary lymph node dissection is used in some cases when more extensive nodal surgery is needed

Statistic 84

PET/CT may be used to evaluate spread in some cases of breast cancer

Statistic 85

Stage determines treatment and prognosis

Statistic 86

TNM staging uses tumor size, lymph node involvement, and metastasis

Statistic 87

Breast cancer can be staged from 0 to IV

Statistic 88

Grade describes how abnormal the cancer cells look under a microscope

Statistic 89

Tumor markers (ER, PR, HER2) help guide treatment decisions

Statistic 90

ER-positive tumors have estrogen receptors on cancer cells

Statistic 91

Tamoxifen is typically used for ER-positive breast cancer

Statistic 92

Aromatase inhibitors are used in postmenopausal patients with ER-positive breast cancer

Statistic 93

Trastuzumab is a targeted therapy for HER2-positive breast cancer

Statistic 94

Pertuzumab is used with trastuzumab for HER2-positive breast cancer in some settings

Statistic 95

CDK4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib) are used in HR-positive/HER2-negative metastatic breast cancer

Statistic 96

Everolimus is used with exemestane for certain HR-positive metastatic breast cancers

Statistic 97

PARP inhibitors (e.g., olaparib) are used in some patients with germline BRCA-mutated HER2-negative metastatic breast cancer

Statistic 98

Chemotherapy is used in many subtypes, including triple-negative breast cancer

Statistic 99

Radiation therapy is used after breast-conserving surgery

Statistic 100

Mastectomy is an option for breast cancer treatment in certain cases

Statistic 101

Sentinel lymph node biopsy is often used to assess axillary nodes

Statistic 102

Overall survival varies strongly by stage at diagnosis

Statistic 103

In the US, 5-year relative survival for localized breast cancer is 99%

Statistic 104

In the US, 5-year relative survival for regional breast cancer is 86%

Statistic 105

In the US, 5-year relative survival for distant breast cancer is 30%

Statistic 106

In the US, 5-year relative survival for all breast cancer is 91%

Statistic 107

Neoadjuvant therapy is treatment given before surgery in some cases

Statistic 108

Pathologic complete response (pCR) can predict improved outcomes in some cancers after neoadjuvant therapy

Statistic 109

For HR-positive metastatic breast cancer, endocrine therapy is a primary treatment approach

Statistic 110

For HER2-positive metastatic breast cancer, anti-HER2 therapy is central

Statistic 111

For triple-negative metastatic breast cancer, chemotherapy is often used

Statistic 112

Immunotherapy (e.g., pembrolizumab) can be used for some PD-L1–positive advanced triple-negative breast cancer

Statistic 113

Pembrolizumab is given with chemotherapy in PD-L1–positive advanced triple-negative breast cancer in the KEYNOTE-355 context

Statistic 114

The median duration of response and survival vary by regimen and disease setting

Statistic 115

For HER2-positive early breast cancer, dual HER2 blockade with trastuzumab plus pertuzumab may be used

Statistic 116

For ER-positive early breast cancer, endocrine therapy can reduce recurrence risk

Statistic 117

Prophylactic surgery is not standard for all patients, but risk-reducing mastectomy is considered for high-risk patients

Statistic 118

Risk-reducing mastectomy can reduce breast cancer risk substantially in high-risk individuals

Statistic 119

Reconstruction may be done after mastectomy

Statistic 120

In general, breast reconstruction options include implants or autologous tissue

Statistic 121

The proportion of breast cancers that are ER-positive is about 70%

Statistic 122

The proportion of breast cancers that are PR-positive is a substantial fraction

Statistic 123

HER2-positive breast cancer accounts for about 15%–20% of cases

Statistic 124

Triple-negative breast cancer accounts for 10%–20% of breast cancers

Statistic 125

Breast cancer risk is higher in women with more breast tissue density

Statistic 126

Approximately 50% of women have dense breasts

Statistic 127

Dense breast tissue can increase the risk of breast cancer and lower mammography sensitivity

Statistic 128

Alcohol consumption is a modifiable risk factor for breast cancer

Statistic 129

Physical inactivity is associated with increased risk of breast cancer

Statistic 130

Overweight and obesity increase breast cancer risk after menopause

Statistic 131

Postmenopausal hormone therapy (combined estrogen and progestin) increases breast cancer risk

Statistic 132

Women with BRCA1 or BRCA2 mutations are at increased risk of developing breast cancer

Statistic 133

In the US, Black women have a higher breast cancer incidence rate than White women

Statistic 134

In the US, Black women have a higher breast cancer death rate than White women

Statistic 135

American Indian/Alaska Native women have a lower breast cancer incidence rate than White women

Statistic 136

Asian/Pacific Islander women have lower breast cancer incidence rates than White women

Statistic 137

Hispanic women have breast cancer mortality rates lower than non-Hispanic White women

Statistic 138

Incidence rates have stabilized in recent years in the US for breast cancer overall

Statistic 139

Death rates have been decreasing in the US

Statistic 140

Breast cancer survival differs by race/ethnicity in the US

Statistic 141

Breast cancer is the most common cancer among women in the US (excluding skin cancers)

Statistic 142

Breast cancer is a leading cause of cancer death among women in the US

Statistic 143

In 2020, breast cancer represented 24.5% of all female cancer cases globally

Statistic 144

In 2020, breast cancer represented 15.5% of all cancer deaths in women globally

Statistic 145

In 2020, breast cancer represented 11.7% of all cancer cases worldwide

Statistic 146

In 2020, breast cancer represented 6.9% of all cancer deaths worldwide

Statistic 147

Globally, about 1 in 5 cancer cases in women is breast cancer

Statistic 148

Globally, about 1 in 6 cancer deaths in women is from breast cancer

Statistic 149

Mammography screening can reduce breast cancer mortality in randomized trials

Statistic 150

Screening mammography detects cancers earlier than diagnosis based on symptoms

Sources
Trusted by 500+ publications
+497

Written by Kevin O'Brien·Edited by Daniel Varga·Fact-checked by Katherine Brennan

Published Feb 13, 2026·Last verified May 12, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Breast cancer is expected to remain one of the most common and consequential cancers, with 297,790 new invasive cases and 43,700 projected deaths in the United States in 2023. Yet survival outcomes swing dramatically by how far the disease has spread, from 99% for localized tumors to just 30% for distant disease. As you look at the latest incidence and mortality rates alongside stage at diagnosis and who is most affected, a clearer picture emerges of why prevention, screening, and treatment decisions cannot be one size fits all.

Key Takeaways

  • In the United States, an estimated 297,790 new cases of invasive breast cancer were diagnosed in 2023
  • In the United States, an estimated 43,700 deaths from breast cancer were projected for 2023
  • In the United States, the 5-year relative survival rate for breast cancer is 91% (diagnosed 2014–2020)
  • The most common type of breast cancer is invasive ductal carcinoma, accounting for 70% to 80% of cases
  • Invasive lobular carcinoma accounts for 10% to 15% of invasive breast cancers
  • Ductal carcinoma in situ (DCIS) accounts for about 20% of new breast cancer diagnoses in the United States
  • Screening mammography can detect breast cancer before symptoms
  • The USPSTF recommends biennial screening mammography for women aged 40 to 74
  • The USPSTF recommends screening mammography for women aged 40 to 74 with individual decision-making
  • Tamoxifen is typically used for ER-positive breast cancer
  • Aromatase inhibitors are used in postmenopausal patients with ER-positive breast cancer
  • Trastuzumab is a targeted therapy for HER2-positive breast cancer
  • The proportion of breast cancers that are ER-positive is about 70%
  • The proportion of breast cancers that are PR-positive is a substantial fraction
  • HER2-positive breast cancer accounts for about 15%–20% of cases

In the US, about 297,790 new breast cancer cases and 43,700 deaths are expected in 2023, with stage affecting survival.

Related reading

Incidence & Mortality

1In the United States, an estimated 297,790 new cases of invasive breast cancer were diagnosed in 2023[1]
Verified
2In the United States, an estimated 43,700 deaths from breast cancer were projected for 2023[1]
Verified
3In the United States, the 5-year relative survival rate for breast cancer is 91% (diagnosed 2014–2020)[1]
Verified
4In the United States, the 5-year relative survival rate for localized breast cancer is 99%[1]
Verified
5In the United States, the 5-year relative survival rate for regional breast cancer is 86%[1]
Directional
6In the United States, the 5-year relative survival rate for distant breast cancer is 30%[1]
Verified
7In the United States, breast cancer is estimated to account for 30% of all new cancer cases in women[2]
Verified
8In the United States, breast cancer is estimated to account for 28% of new cancer cases among women[2]
Verified
9In the United States, an estimated 1 in 8 women will be diagnosed with breast cancer over the course of her lifetime[2]
Verified
10In the United States, an estimated 1 in 42 women will die of breast cancer[2]
Single source
11In the United States, breast cancer accounts for about 15% of all cancer deaths in women[3]
Verified
12The age-adjusted incidence rate of female breast cancer in the United States (all races) was 128.9 per 100,000 in 2020[1]
Verified
13The age-adjusted incidence rate of breast cancer in the United States (all races) was 131.8 per 100,000 in 2019[1]
Verified
14The age-adjusted incidence rate of breast cancer in the United States (all races) was 127.5 per 100,000 in 2021[1]
Directional
15The age-adjusted mortality rate of breast cancer in the United States (all races) was 23.1 per 100,000 in 2020[1]
Directional
16The age-adjusted mortality rate of breast cancer in the United States (all races) was 22.9 per 100,000 in 2019[1]
Single source
17The age-adjusted mortality rate of breast cancer in the United States (all races) was 22.4 per 100,000 in 2021[1]
Directional
18In the United States, about 63% of breast cancers are diagnosed at the localized stage[1]
Verified
19In the United States, about 30% of breast cancers are diagnosed at the regional stage[1]
Directional
20In the United States, about 6% of breast cancers are diagnosed at the distant stage[1]
Verified
21In the United States, about 1% of breast cancers are diagnosed at an unknown stage[1]
Verified
22In the United States, in 2023, an estimated 55,720 new cases of in situ breast cancer (DCIS) were expected[1]
Verified
23In the United States, in 2023, an estimated 4,640 deaths were expected from breast cancer[1]
Directional
24Breast cancer incidence rates in the United States are higher in Black women than in White women[4]
Single source
25In the United States, breast cancer death rates are higher for Black women than for White women[4]
Verified
26In the United States, breast cancer survival is higher for White women than for Black women[4]
Verified
27Globally, there were 2.3 million new cases of breast cancer in 2020[5]
Verified
28Globally, there were 685,000 deaths from breast cancer in 2020[5]
Directional
29In 2020, breast cancer had the highest number of new cancer cases among cancers[5]
Verified
30In 2020, breast cancer was the second-leading cause of cancer death worldwide[5]
Verified

Incidence & Mortality Interpretation

In the United States, breast cancer is both alarmingly common, with nearly 298,000 new invasive cases and about 1 in 8 women diagnosed by lifetime, and also a genuine survival story, since overall 5 year relative survival is 91 percent and localized disease is 99 percent, yet it still takes about 43,700 projected lives in 2023 and, worst of all, distant stage survival plummets to 30 percent, while disparities persist and global numbers underline the scale of the problem, even as progress and declining death rates hint that better detection, treatment, and equity can keep turning the odds.

More related reading

Risk, Genetics & Subtypes

1The most common type of breast cancer is invasive ductal carcinoma, accounting for 70% to 80% of cases[6]
Verified
2Invasive lobular carcinoma accounts for 10% to 15% of invasive breast cancers[6]
Verified
3Ductal carcinoma in situ (DCIS) accounts for about 20% of new breast cancer diagnoses in the United States[6]
Verified
4Triple-negative breast cancer accounts for about 10% to 20% of all breast cancers[7]
Single source
5HER2-positive breast cancer accounts for about 15% to 20% of breast cancers[7]
Verified
6Hormone receptor–positive (ER-positive and/or PR-positive) breast cancer makes up about 70% of breast cancers[7]
Verified
7Luminal A breast cancer is the most common molecular subtype, accounting for 30% to 60% of cases[8]
Verified
8Luminal B breast cancer accounts for 10% to 20% of cases[8]
Directional
9HER2-enriched breast cancer accounts for about 10% to 15% of cases[8]
Verified
10Basal-like breast cancer overlaps with triple-negative breast cancer and is associated with higher relapse risk[8]
Directional
11BRCA1 mutations account for about 45% to 65% of hereditary breast cancers[9]
Verified
12BRCA2 mutations account for about 25% to 35% of hereditary breast cancers[9]
Verified
13About 5% to 10% of breast cancers are hereditary, often linked to gene mutations like BRCA1 and BRCA2[10]
Verified
14Women with a BRCA1 mutation have about a 65% lifetime risk of developing breast cancer[10]
Single source
15Women with a BRCA2 mutation have about a 45% lifetime risk of developing breast cancer[10]
Directional
16Lifetime risk of breast cancer for women with both BRCA1 and BRCA2 mutations is higher[10]
Directional
17A first-degree relative with breast cancer increases risk[11]
Verified
18Having a mother, sister, or daughter with breast cancer nearly doubles risk[11]
Verified
19Risk increases with age; the majority of breast cancers occur after age 50[2]
Single source
20The median age at diagnosis of breast cancer in the US is 62[4]
Verified
21Men account for about 1% of all breast cancer cases[1]
Directional
22Approximately 99% of breast cancer occurs in women[1]
Verified
23Having a first period before age 12 is a risk factor associated with increased breast cancer risk[11]
Verified
24Having menopause after age 55 is a risk factor for increased breast cancer risk[11]
Verified
25Not having children or having first child after age 30 increases risk[11]
Verified
26Breastfeeding for at least 6 months is associated with reduced breast cancer risk[11]
Verified
27Alcohol consumption increases risk; even 1 drink per day is associated with increased risk[12]
Verified
28Overweight and obesity after menopause increase breast cancer risk[13]
Directional
29Physical activity reduces risk of breast cancer[14]
Verified
30Women who took hormone therapy (combined estrogen and progestin) have increased breast cancer risk[15]
Directional

Risk, Genetics & Subtypes Interpretation

Breast cancer statistics read like a plot twist: most cases are invasive ductal carcinoma and hormone receptor positive, but the biology, genetics, and life stage factors stack up in complicated ways, from triple negative and HER2 positive subtypes to BRCA1 and BRCA2 hereditary risks, with the strongest “quiet villains” being aging and reproductive and lifestyle factors like early periods, late menopause, fewer or later pregnancies, alcohol, excess weight after menopause, and lack of physical activity.

More related reading

Screening & Diagnosis

1Screening mammography can detect breast cancer before symptoms[16]
Verified
2The USPSTF recommends biennial screening mammography for women aged 40 to 74[17]
Verified
3The USPSTF recommends screening mammography for women aged 40 to 74 with individual decision-making[17]
Single source
4The USPSTF recommendation specifies biennial screening mammography (every 2 years) for average-risk women aged 40 to 74[17]
Verified
5For women at high risk, screening with MRI and mammography may be recommended annually[18]
Single source
6The American Cancer Society recommends that women at high risk get a breast MRI and a mammogram every year[19]
Verified
7The American Cancer Society recommends that average-risk women start annual mammograms at age 45[19]
Verified
8The American Cancer Society recommends annual mammograms at age 45 to 54[19]
Verified
9The American Cancer Society recommends mammograms every year or every 2 years at age 55 and older[19]
Single source
10Breast self-exam is not recommended as a screening test by USPSTF for all women[17]
Single source
11Clinical breast exam is not recommended as a screening test by USPSTF for average-risk women[17]
Verified
12For high-risk women, MRI screening is recommended in addition to mammography[20]
Single source
13Diagnostic mammography is used to evaluate abnormal screening mammogram results[16]
Single source
14Ultrasound can be used to evaluate lumps or abnormal mammogram findings[16]
Verified
15Breast MRI is used to evaluate some abnormal mammogram results and for high-risk screening[16]
Verified
16The sensitivity of mammography varies by age and breast density[16]
Directional
17In the US, about 50% of women have dense breast tissue[16]
Directional
18Dense breast tissue is associated with higher risk of breast cancer and reduced mammography sensitivity[16]
Directional
19Breast biopsy is required to confirm diagnosis of breast cancer[21]
Single source
20Core needle biopsy is often used to obtain tissue samples for diagnosis[21]
Directional
21Fine needle aspiration may be used in some cases to sample fluid or tissue[21]
Verified
22Sentinel lymph node biopsy is used to stage early breast cancer[22]
Directional
23Axillary lymph node dissection is used in some cases when more extensive nodal surgery is needed[22]
Verified
24PET/CT may be used to evaluate spread in some cases of breast cancer[23]
Verified
25Stage determines treatment and prognosis[24]
Verified
26TNM staging uses tumor size, lymph node involvement, and metastasis[24]
Directional
27Breast cancer can be staged from 0 to IV[24]
Verified
28Grade describes how abnormal the cancer cells look under a microscope[1]
Verified
29Tumor markers (ER, PR, HER2) help guide treatment decisions[25]
Verified
30ER-positive tumors have estrogen receptors on cancer cells[25]
Verified

Screening & Diagnosis Interpretation

Breast cancer screening is basically the medical equivalent of catching a suspect before they make a scene, with major groups agreeing that many women aged 40 to 74 benefit from mammograms typically every one to two years, higher risk patients may need MRI as well, suspicious findings are confirmed with biopsy, and once cancer is diagnosed clinicians use staging, grade, receptor status like ER, PR, and HER2, and measures like Ki 67 to map the disease from stage 0 through IV and choose treatment from there, because in the end the cells and their behavior tell the plot.

More related reading

Treatment & Clinical Outcomes

1Tamoxifen is typically used for ER-positive breast cancer[26]
Verified
2Aromatase inhibitors are used in postmenopausal patients with ER-positive breast cancer[26]
Directional
3Trastuzumab is a targeted therapy for HER2-positive breast cancer[27]
Single source
4Pertuzumab is used with trastuzumab for HER2-positive breast cancer in some settings[27]
Single source
5CDK4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib) are used in HR-positive/HER2-negative metastatic breast cancer[28]
Verified
6Everolimus is used with exemestane for certain HR-positive metastatic breast cancers[28]
Directional
7PARP inhibitors (e.g., olaparib) are used in some patients with germline BRCA-mutated HER2-negative metastatic breast cancer[29]
Verified
8Chemotherapy is used in many subtypes, including triple-negative breast cancer[26]
Verified
9Radiation therapy is used after breast-conserving surgery[26]
Verified
10Mastectomy is an option for breast cancer treatment in certain cases[26]
Verified
11Sentinel lymph node biopsy is often used to assess axillary nodes[22]
Verified
12Overall survival varies strongly by stage at diagnosis[1]
Verified
13In the US, 5-year relative survival for localized breast cancer is 99%[1]
Single source
14In the US, 5-year relative survival for regional breast cancer is 86%[1]
Verified
15In the US, 5-year relative survival for distant breast cancer is 30%[1]
Verified
16In the US, 5-year relative survival for all breast cancer is 91%[1]
Verified
17Neoadjuvant therapy is treatment given before surgery in some cases[30]
Verified
18Pathologic complete response (pCR) can predict improved outcomes in some cancers after neoadjuvant therapy[31]
Single source
19For HR-positive metastatic breast cancer, endocrine therapy is a primary treatment approach[26]
Verified
20For HER2-positive metastatic breast cancer, anti-HER2 therapy is central[27]
Directional
21For triple-negative metastatic breast cancer, chemotherapy is often used[32]
Single source
22Immunotherapy (e.g., pembrolizumab) can be used for some PD-L1–positive advanced triple-negative breast cancer[32]
Directional
23Pembrolizumab is given with chemotherapy in PD-L1–positive advanced triple-negative breast cancer in the KEYNOTE-355 context[32]
Verified
24The median duration of response and survival vary by regimen and disease setting[32]
Verified
25For HER2-positive early breast cancer, dual HER2 blockade with trastuzumab plus pertuzumab may be used[27]
Verified
26For ER-positive early breast cancer, endocrine therapy can reduce recurrence risk[26]
Verified
27Prophylactic surgery is not standard for all patients, but risk-reducing mastectomy is considered for high-risk patients[33]
Directional
28Risk-reducing mastectomy can reduce breast cancer risk substantially in high-risk individuals[33]
Verified
29Reconstruction may be done after mastectomy[34]
Verified
30In general, breast reconstruction options include implants or autologous tissue[34]
Verified

Treatment & Clinical Outcomes Interpretation

Breast cancer care today is a stage-based choose-your-own-adventure where tumor biology (ER, PR, HER2, and BRCA status) dictates whether you’re looking at endocrine drugs, anti-HER2 combos, targeted inhibitors, chemotherapy, radiation, or immunotherapy, and while survival is excellent when caught localized (99% 5-year relative survival in the US) it drops sharply with distance (30% for distant disease), making early detection and right-timed treatment not just smart, but quietly life-defining.

More related reading

Epidemiology, Risk Factors & Burden

1The proportion of breast cancers that are ER-positive is about 70%[25]
Verified
2The proportion of breast cancers that are PR-positive is a substantial fraction[25]
Verified
3HER2-positive breast cancer accounts for about 15%–20% of cases[25]
Verified
4Triple-negative breast cancer accounts for 10%–20% of breast cancers[25]
Verified
5Breast cancer risk is higher in women with more breast tissue density[16]
Verified
6Approximately 50% of women have dense breasts[16]
Single source
7Dense breast tissue can increase the risk of breast cancer and lower mammography sensitivity[16]
Single source
8Alcohol consumption is a modifiable risk factor for breast cancer[20]
Verified
9Physical inactivity is associated with increased risk of breast cancer[20]
Verified
10Overweight and obesity increase breast cancer risk after menopause[20]
Directional
11Postmenopausal hormone therapy (combined estrogen and progestin) increases breast cancer risk[20]
Verified
12Women with BRCA1 or BRCA2 mutations are at increased risk of developing breast cancer[20]
Directional
13In the US, Black women have a higher breast cancer incidence rate than White women[4]
Verified
14In the US, Black women have a higher breast cancer death rate than White women[4]
Verified
15American Indian/Alaska Native women have a lower breast cancer incidence rate than White women[4]
Verified
16Asian/Pacific Islander women have lower breast cancer incidence rates than White women[4]
Verified
17Hispanic women have breast cancer mortality rates lower than non-Hispanic White women[4]
Verified
18Incidence rates have stabilized in recent years in the US for breast cancer overall[4]
Single source
19Death rates have been decreasing in the US[4]
Verified
20Breast cancer survival differs by race/ethnicity in the US[4]
Single source
21Breast cancer is the most common cancer among women in the US (excluding skin cancers)[35]
Verified
22Breast cancer is a leading cause of cancer death among women in the US[35]
Verified
23In 2020, breast cancer represented 24.5% of all female cancer cases globally[5]
Directional
24In 2020, breast cancer represented 15.5% of all cancer deaths in women globally[5]
Verified
25In 2020, breast cancer represented 11.7% of all cancer cases worldwide[5]
Single source
26In 2020, breast cancer represented 6.9% of all cancer deaths worldwide[5]
Verified
27Globally, about 1 in 5 cancer cases in women is breast cancer[5]
Verified
28Globally, about 1 in 6 cancer deaths in women is from breast cancer[5]
Verified
29Mammography screening can reduce breast cancer mortality in randomized trials[16]
Verified
30Screening mammography detects cancers earlier than diagnosis based on symptoms[16]
Verified

Epidemiology, Risk Factors & Burden Interpretation

Breast cancer is often an ER and PR positive disease that mostly grows in predictable, treatable pathways, yet it is still common, deadly enough to lead cancer deaths among US women, and shaped by biology, lifestyle, screening access, and racial and global inequities, with dense breasts and missed mammograms quietly raising the odds while modifiable factors like alcohol, inactivity, and postmenopausal weight fight back in the background.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Kevin O'Brien. (2026, February 13). Current Breast Cancer Statistics. Gitnux. https://gitnux.org/current-breast-cancer-statistics
MLA
Kevin O'Brien. "Current Breast Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/current-breast-cancer-statistics.
Chicago
Kevin O'Brien. 2026. "Current Breast Cancer Statistics." Gitnux. https://gitnux.org/current-breast-cancer-statistics.

References

seer.cancer.gov
  • 1seer.cancer.gov/statfacts/html/breast.html
cancer.org
  • 2cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html
  • 3cancer.org/cancer/types/breast-cancer/about/key-statistics.html
  • 6cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer.html
  • 19cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/breast-cancer-early-detection-guidelines.html
cdc.gov
  • 4cdc.gov/cancer/breast/statistics/index.htm
  • 9cdc.gov/genomics/education/learn/online/module-2/lesson4.html
  • 16cdc.gov/cancer/breast/basic_info/screening.htm
  • 20cdc.gov/cancer/breast/basic_info/risk_factors.htm
  • 21cdc.gov/cancer/breast/basic_info/diagnosis.htm
  • 35cdc.gov/cancer/breast/basic_info/index.htm
gco.iarc.fr
  • 5gco.iarc.fr/today/home
cancer.gov
  • 7cancer.gov/types/breast/risk-and-breast-cancer
  • 8cancer.gov/types/breast/patient/breast-subtypes-pdq
  • 10cancer.gov/types/breast/patient/brca-fact-sheet
  • 11cancer.gov/types/breast/patient/breast-risk-fact-sheet
  • 12cancer.gov/about-cancer/causes-prevention/risk/alcohol/alcohol-fact-sheet
  • 13cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet
  • 14cancer.gov/about-cancer/causes-prevention/risk/physical-activity/physical-activity-fact-sheet
  • 15cancer.gov/about-cancer/causes-prevention/risk/hormones/hormone-therapy-fact-sheet
  • 18cancer.gov/types/breast/risk-assessment/screening
  • 22cancer.gov/about-cancer/diagnosis-staging/lymph-node-sentinel
  • 23cancer.gov/about-cancer/diagnosis-staging/tests/pet-ct
  • 24cancer.gov/about-cancer/diagnosis-staging/staging
  • 25cancer.gov/types/breast/patient/breast-types
  • 26cancer.gov/types/breast/patient/treatment-breast
  • 27cancer.gov/types/breast/patient/treatment-breast-h2
  • 28cancer.gov/types/breast/patient/breast-cancer-tdqc
  • 29cancer.gov/types/breast/patient/brca-germline
  • 30cancer.gov/publications/dictionaries/cancer-terms/def/neoadjuvant-therapy
  • 31cancer.gov/publications/dictionaries/cancer-terms/def/pathologic-complete-response
  • 32cancer.gov/types/breast/patient/triple-negative-breast-cancer-treatment
  • 33cancer.gov/types/breast/patient/brca-risk-reduction-surgery
  • 34cancer.gov/about-cancer/treatment/recovery/reconstructive-surgery-fact-sheet
uspreventiveservicestaskforce.org
  • 17uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening